What is an appropriate massive transfusion protocol for use in anesthesia?

Massive Transfusion Protocol for Anesthesia

Implement a structured massive transfusion protocol that prioritizes early hemostatic resuscitation with balanced blood component therapy, aggressive warming, and rapid hemorrhage control to prevent the lethal triad of acidosis, hypothermia, and coagulopathy.

Protocol Activation and Initial Response

Activate the massive transfusion protocol immediately when massive hemorrhage is declared, defined as anticipated blood loss of 1-1.5 blood volumes or clinical instability (systolic BP < 90 mmHg and/or heart rate > 110 bpm) despite initial resuscitation 1, 2. The protocol must mobilize clinical, laboratory, and logistic responses simultaneously 1.

Immediate Hemorrhage Control

• Control obvious bleeding first using direct pressure, tourniquets, or hemostatic dressings before focusing on transfusion 1, 3
• Establish large-bore intravenous access with maximum gauge cannulas; use intraosseous or surgical venous access if peripheral access fails 3
• Deliver high-flow oxygen to all patients 3

Blood Component Administration Strategy

Red Blood Cell Transfusion

• Start with uncrossmatched O-negative blood only if blood is needed immediately, then transition to group-specific blood without antibody screening (as circulating antibodies are minimal), and finally to crossmatched units 1
• Use blood component administration sets incorporating 170-200 μm filters for all blood products 1
• Administer platelets via a clean giving set, as one previously used for red cells may cause platelets to adhere and reduce effective dosing 1

Fresh Frozen Plasma (FFP)

Administer early FFP at 15 ml/kg to prevent established coagulopathy when a senior clinician anticipates massive hemorrhage 1. A fibrinogen < 1 g/L or PT/aPTT > 1.5 times normal represents established hemostatic failure predictive of microvascular bleeding 1. Established coagulopathy requires more than 15 ml/kg FFP to correct 1.

Fibrinogen Replacement

The most effective way to achieve rapid fibrinogen replacement is by giving fibrinogen concentrate or cryoprecipitate, targeting fibrinogen > 1.5 g/L 1, 3. Always measure fibrinogen using the Clauss method; derived fibrinogen values are misleading and should be avoided 3.

Platelet Transfusion

• Maintain a minimum target platelet count of 75 × 10⁹/L in massive hemorrhage 1
• For major surgery without active bleeding, maintain platelets > 50 × 10⁹/L 2
• For neurosurgery or posterior segment ophthalmic surgery, maintain > 100 × 10⁹/L 2

Balanced Resuscitation Ratios

Reserve 1:1:1 red cell:FFP:platelet regimens (as used by the military) for the most severely traumatized patients 1. This approach prevents dilutional coagulopathy in exsanguinating hemorrhage 3.

Equipment and Warming Requirements

Blood Warming

All intravenous fluids ≥ 500 ml and blood components must be warmed to 37°C in all adults undergoing elective or emergency surgery under general or regional anesthesia 1. This equipment must be available in all emergency rooms and theatre suites 1.

• Use only approved, specifically designed blood warming equipment with visible thermometer and audible warning 1
• Monitor settings regularly throughout transfusion 1
• Never warm blood using improvisations such as warm water, microwave, or radiator 1
• Greatest benefit comes from warming red cells (stored at 4°C) rather than platelets (22 ± 2°C) or FFP/cryoprecipitate (thawed to 37°C) 1

Rapid Infusion Devices

• Use rapid infusion devices capable of 6-30 L/h when large volumes must be infused quickly 1
• These typically incorporate blood-warming devices 1
• Only use devices verified as safe by manufacturer and CE-marked 1
• Monitor volume delivered regularly to ensure expected rate 1

Pressure Devices

External pressure devices enable administration of a unit of red cells within minutes and should only be used in emergency situations with large-gauge venous access 1.

Pharmacologic Adjuncts

Tranexamic Acid

Administer tranexamic acid 1 g over 10 minutes followed by 1 g over 8 hours when accelerated fibrinolysis is suspected or identified 1, 3. Accelerated fibrinolysis can be identified by laboratory assay of D-dimers, fibrin degradation products, or point-of-care coagulation monitoring (TEG/ROTEM) 1.

• Few adverse events or side effects occur with tranexamic acid in massive hemorrhage 1
• Use repeat doses with caution in renal impairment (drug excreted unchanged by kidneys) 1
• Contraindicated in subarachnoid hemorrhage due to risk of cerebral edema and infarction 1

Prothrombin Complex Concentrate (PCC)

For rapid reversal of vitamin K antagonists in major or life-threatening bleeding, use PCC at 25 IU/kg with 5-10 mg intravenous vitamin K 2. Check INR 30 minutes after dosing 2. Important risks include thrombosis (arterial and venous) and hypersensitivity reactions 2.

Laboratory Monitoring

Initial Testing

• Draw baseline studies immediately: complete blood count, PT, aPTT, Clauss fibrinogen (not derived), and type-and-crossmatch 3
• Perform point-of-care coagulation testing (TEG or ROTEM) when available to guide hemostatic therapy 3

Ongoing Monitoring

Monitor coagulation parameters, hemoglobin, and arterial blood gases continuously in critical care 3.

Resuscitation Strategy

Permissive Hypotension

Do not normalize blood pressure before hemorrhage control, as this may exacerbate bleeding 3. Assess perfusion clinically: consciousness, ability to speak, and palpable peripheral pulse indicate adequate perfusion; normal blood pressure is not required before definitive hemorrhage control 3.

Fluid Management

Minimize crystalloid administration to prevent dilutional coagulopathy 3. Withhold vasopressors until active bleeding is controlled 3.

Cell Salvage

Encourage use of cell salvage in all cases of massive hemorrhage 1. When using red cell salvage, a 40-μm filter may be indicated if small bone fragments contaminate the surgical field 1.

Post-Resuscitation Management

• Admit to critical care unit for continuous monitoring 3
• Commence standard venous thromboprophylaxis as soon as possible after hemostasis is secured, as patients develop a prothrombotic state following massive hemorrhage 1, 3

Critical Pitfalls to Avoid

• Avoid hyperventilation, inadequate blood warming, and overenthusiastic correction of metabolic acidosis, as these shift the oxygen dissociation curve left and worsen tissue oxygenation 4
• Do not use "blind" substitution of coagulation products without laboratory or clinical guidance 4
• Never use derived fibrinogen values for clinical decisions 3
• Do not delay protocol activation waiting for laboratory confirmation 1